# Spyre Therapeutics, Inc. (SYRE) stock: price and valuation

URL: https://funkfolio.com/stock/SYRE

> Spyre Therapeutics, Inc. (SYRE) trades at $93.41 and is worth $8.87B. Valuation against its own history and up to 20 years of financials.

---

## Spyre Therapeutics, Inc. (SYRE)

Spyre Therapeutics, Inc. (SYRE) is a healthcare company (biotechnology) based in the United States. The share price is $93.41, down 6.00% on the day, which values the company at $8.87B. Price as of 17 Nov 2026, 20:44 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $93.41 −6.00% today
- **Market value:** $8.87B
- **200-week average:** $32.59 187% above
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 20:44 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Spyre Therapeutics, Inc. in more detail

SYRE trades at -25.3× next year's expected earnings. It sits 187% above its 200-week average of $32.59.

Worth checking: Share count keeps rising.

1 of the superinvestors tracked here hold SYRE, including Brandon Haley (0.2% of the portfolio).

### Superinvestors holding SYRE

1 of the investors tracked here report a position in their latest 13F filing.

- [Brandon Haley Holocene Advisors](https://funkfolio.com/gurus/brandon-haley) 0.21% of portfolio · $90.1M · new · Q2 2026

### Health Care companies of similar size

- [BioMarin Pharmaceutical BMRN](https://funkfolio.com/stock/BMRN)
- [Avantor AVTR](https://funkfolio.com/stock/AVTR)
- [Ensign Group ENSG](https://funkfolio.com/stock/ENSG)
- [Vaxcyte PCVX](https://funkfolio.com/stock/PCVX)
- [Bio-Rad Laboratories BIO](https://funkfolio.com/stock/BIO)
- [Molina Healthcare MOH](https://funkfolio.com/stock/MOH)
- [Qiagen QGEN](https://funkfolio.com/stock/QGEN)
- [Insulet PODD](https://funkfolio.com/stock/PODD)
- [Bruker BRKR](https://funkfolio.com/stock/BRKR)
- [Globus Medical GMED](https://funkfolio.com/stock/GMED)
- [Madrigal Pharmaceuticals MDGL](https://funkfolio.com/stock/MDGL)
- [Henry Schein HSIC](https://funkfolio.com/stock/HSIC)

Side by side: [SYRE vs QGEN (Spyre Therapeutics, Inc. vs Qiagen)](https://funkfolio.com/compare/qgen-vs-syre) [SYRE vs PODD (Spyre Therapeutics, Inc. vs Insulet)](https://funkfolio.com/compare/podd-vs-syre) [SYRE vs MOH (Spyre Therapeutics, Inc. vs Molina Healthcare)](https://funkfolio.com/compare/moh-vs-syre) [SYRE vs BIO (Spyre Therapeutics, Inc. vs Bio-Rad Laboratories)](https://funkfolio.com/compare/bio-vs-syre) [SYRE vs PCVX (Spyre Therapeutics, Inc. vs Vaxcyte)](https://funkfolio.com/compare/pcvx-vs-syre)

[All health care companies by market value](https://funkfolio.com/companies/sector/health-care) [Largest companies in the United States](https://funkfolio.com/companies/country/united-states) [All stocks A–Z](https://funkfolio.com/stocks)

### Spyre Therapeutics, Inc. (SYRE): questions and answers

**What is Spyre Therapeutics, Inc.'s market cap?**

Spyre Therapeutics, Inc. is valued at $8.87B at a share price of $93.41.

**Is SYRE above its 200-week moving average?**

Yes. SYRE is 186.6% above its 200-week average of $32.59. Long-term investors watch that line because strong companies rarely trade below it for long.

**Does SYRE pay a dividend?**

Spyre Therapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own SYRE?**

In their latest quarterly filings, Brandon Haley (0.2% of the portfolio) hold SYRE. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Spyre Therapeutics, Inc. (SYRE) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SYRE

Underlying data: Yahoo Finance; company filings with the SEC.
